### **MEDLINE®**



MEDLINE is the U.S. National Library of Medicine (NLM) premier bibliographic database. It contains references to journal articles in life sciences with a concentration on biomedicine and health. This is broadly defined to encompass those areas of the life sciences, behavioral sciences, chemical sciences, and bioengineering needed by health professionals and others engaged in basic research and clinical care, public health, health policy development, or related educational activities. MEDLINE also covers life sciences vital to biomedical practitioners, researchers, and educators, including aspects of biology, environmental science, marine biology, plant and animal science as well as biophysics and chemistry.

A distinctive feature of MEDLINE is that the documents are indexed with NLM Medical Subject Headings (MeSH®). Dialog™ provides an interactive thesaurus so searchers can take full advantage of these and easily find the right terms for subjects while viewing their broader and narrower hierarchies, subheadings and scope notes.

The greater part of MEDLINE consists of fully indexed documents, but there are also several types of 'in process' documents, including those known as 'Publisher' documents, which are early-release, electronic versions posted to the web before full bibliographic information is known.

MEDLINE covers virtually every area in the broad field of biomedicine, including, but not limited to, the following:

Clinical Medicine Environmental, Public and Occupational Health

Dentistry Veterinary Medicine
Nursing Nutrition

Population and Reproductive Biology
Pharmacology and Pharmaceutics
Pathology
Anatomy and Physiology

Psychiatry and Psychology Toxicology

Use MEDLINE to answer such questions as:

- What is the latest progress in developing a vaccine for the zika virus?
- Have any clinical trials been conducted on belatacept in kidney transplantation?
- Are there any systematic reviews on the treatment of large non-pedunculated colorectal polyps?
- What are the adverse effects of indomethacin?

Date Coverage 1946 - present Update Frequency Daily (seven days per week) with

annual refresh.

Geographic Coverage International

Journals About 5,600 journals from over 70 countries Document Types Journal articles

**Publisher** 

MEDLINE is produced by the U.S. National Library of Medicine.

National Library of Medicine Customer Services Section 8600 Rockville Pike Bethesda, MD 20894

## Sample document

# **MEDLINE®**

# Citation/Abstract « Back to results

Add to selected items

cancer: a pilot study



Order full text Save to My Research

ΤI

AU, AUFN, AULN PUB

□ Abstract (summary) Translate

AΒ

#### BACKGROUND

A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma.

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate

Sathekge, Mike; Bruchertseifer, Frank; Knoesen, Otto; Reyneke, Florette; Lawal, Ismaheel; et

al. European journal of nuclear medicine and molecular imaging 46.1: 129-138. (Jan

#### METHODS

Seventeen patients with advanced prostate cancer were selected for treatment with 225Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response. In one patient, activity was escalated to 13 MBg in the third cycle, Fourteen patients had three treatment cycles administered, while in three patients treatment was discontinued after two cycles due to good response. Six out of 17 patients received additional treatments after the third cycle. Prostate-specific antigen (PSA) was measured every 4 weeks for PSA response assessment. 68Ga-PSMA-PET/CT was used for functional response assessment before each subsequent treatment cycle. Serial full blood count, renal function test, and liver function were obtained to determine treatment-related side effects.

#### RESULTS

Good antitumor activity assessed by serum PSA level and 68Ga-PSMA-PET/CT was seen in 16/17 patients. In 14/17 patients, PSA decline ≥90% was seen after treatment, including seven patients with undetectable serum PSA following two (2/7) or three cycles (5/7) cycles of 225Ac-PSMA-617. Fifteen of 17 patients had a > 50% decline in lesions avidity for tracer on 68Ga-PSMA-PET/CT including 11 patients with complete resolution (PET-negative and either stable sclerosis on CT for bone or resolution of lymph node metastases) of all metastatic lesions. Grade 1/2 xerostomia was seen in all patients, and none was severe enough to lead to discontinuation of treatment. One patient had with extensive bone marrow metastases and a background anemia developed a grade 3 anemia while another patient with solitary kidney and pre-treatment grade 3 renal failure developed grade 4 renal toxicity following treatment. The group presented with significant palliation of bone pain and reduced toxicity to salivary glands due to de-escalation.

#### CONCLUSIONS

225Ac-PSMA-617 RLT of chemotherapy-naïve patients with advanced metastatic prostate carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy. The remarkable therapeutic efficacy reported in this study could be achieved with reduced toxicity to salivary glands due to de-escalation of administered activities in subsequent treatment cycles. This necessitates further exploration for informing clinical practice and clinical trial design.

☐ Indexing (details) ☐ Cite RF References Appl Radiat Isot. 2016 Dec; 118: 366-374. 27776333.; Eur J Nucl Med Mol Imaging, 2017 Aug;44(8):1258-1268, 28497198.; J Nucl Med. 2015 Jun:56(6):914-20, 25883127.: Prostate. 2017 Jan;77(1):33-40. 27527643.; CA Cancer J Clin. 2018 Jan; 68(1):7-30. 29313949.; Eur J Cancer. 2014 Jun; 50(9):1617-27. 24703899.; Eur J Nucl Med Mol Imaging. 2018 Jan; 45(1):31-37. 28891033.; Eur J Nucl Med Mol Imaging. 2018 Feb; 45(2): 226-234. 29101444.; J Nucl Med. 2018 Jul;59(7):1076-1080. 29269569.; Prostate Cancer. 2016;2016:5653862. 27891254.; Eur Urol. 2012 Jun; 61(6):1079-92. 22424666.; J Nucl Med. 2018 May; 59(5): 795-802. 29326358.; Nucl Med Commun. 2018 Feb;39(2):179-185. 29257006.; Can Urol Assoc J. 2013 Jan-Feb;7(1-2 Suppl 1):S11-7. 23682301.; J Nucl Med. 2016 Dec; 57(12):1941-1944. 27390158.; J Nucl Med. 2017 Oct;58(10):1624-1631. 28408529.; Prostate. 2017 Aug;77(11):1205-1212. 28649735.; Eur Urol. 2014 Feb;65(2):467-79. 24321502.; J Clin Oncol. 2016 Apr 20;34(12):1402-18. 26903579.; Molecules. 2015 Aug 14;20(8):14860-78. 26287143.; Ann Oncol. 2015 Aug; 26(8):1589-604. 26041764.; Appl Radiat Isot. 2005 Mar;62(3):383-7. 15607913.; J Nucl Med. 2017 Feb;58(2):312-319. 27587707.; Lancet Oncol. 2018 Jun; 19(6):825-833. 29752180.; J Nucl Med. 2018 Mar; 59(3): 459-465. 28798031.; Eur J Nucl Med Mol Imaging, 2019 Jan; 46(1):139-147, 30151743.; Curr Radiopharm. 2018;11(3):200-208. 29732998. MESH. SU MeSH Actinium -- adverse effects; **MJMESH** Actinium -- therapeutic use (major); Aged; Aged, 80 and over; Carcinoma -- diagnostic imaging; Carcinoma -- pathology; Carcinoma -- radiotherapy (major); Dipeptides -- adverse effects; Dipeptides -- therapeutic use (major); Edetic Acid -- analogs & derivatives; Heterocyclic Compounds, 1-Ring -- adverse effects; Heterocyclic Compounds, 1-Ring -- therapeutic use (major); Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant -- diagnostic imaging; Prostatic Neoplasms, Castration-Resistant -- pathology;

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Prostatic Neoplasms, Castration-Resistant -- radiotherapy (major);

Radiopharmaceuticals -- adverse effects; Radiopharmaceuticals -- therapeutic use (major)

JCLASS	Journal classification	Index Medicus	
SUBST	Substance	Substance: CAS:	(225)Ac-PSMA-617 0
		Substance: CAS:	Actinium-225 0
		Substance: CAS:	Dipeptides 0
		Substance: CAS:	Heterocyclic Compounds, 1-Ring 0
		Substance: CAS:	Oligopeptides 0
		Substance: CAS:	PSMA-617 0
		Substance: CAS:	Radiopharmaceuticals 0
		Substance: CAS:	Edetic Acid 9G34HU7RV0
		Substance: CAS:	Actinium NIK1K0956U
		Substance: CAS:	Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) ZJ0EKR6M10
IF	Identifier (keyword)	Actinium-225, Radioligand the	Chemotherapy-naïve, PSA response, PSMA, Prostate cancer, erapy
ті	Title	225Ac-PSMA-6 cancer: a pilot	17 in chemotherapy-naive patients with advanced prostate study
AU, AUFN, AULN	Author		$e^{1}$ ; Bruchertseifer, Frank $^{2}$ ; Knoesen, Otto $^{3}$ ; Reyneke, Florette $^{1}$ ;
			el <sup>1</sup> ; Lengana, Thabo <sup>1</sup> ; Davis, Cindy <sup>1</sup> ; Mahapane, Johncy <sup>1</sup> ; a <sup>1</sup> ; Vorster, Mariza <sup>1</sup> ; Morgenstern, Alfred <sup>4</sup>
		corbett, cecen	, vorster, Mariza , Morgenstern, Amed
AF			of Nuclear Medicine, Steve Biko Academic Hospital, University of e Bag X169, Pretoria, 0001, South Africa, South Africa @up.ac.za
			mmission, Joint Research Centre, Directorate for Nuclear Safety arlsruhe, Germany, Germany
			nology Products (NTP), Pelindaba, South Africa, South Africa
		Pretoria, Privat	of Nuclear Medicine, Steve Biko Academic Hospital, University of e Bag X169, Pretoria, 0001, South Africa, European Commission, Centre, Directorate for Nuclear Safety and Security, Karlsruhe, nany
AU	Author e-mail address	mike.sathekge	@up.ac.za
	Correspondence author		e Department of Nuclear Medicine, Steve Biko Academic Hospital, retoria, Private Bag X169, Pretoria, 0001, South Africa.
LA	Language	English	
LS	Language of abstract	English	
DTYPE	Document type	Journal Article	

PUB Publication title European journal of nuclear medicine and molecular imaging VO Volume IS Issue 1 PG Pagination 129-138 ISSN ISSN 1619-7070 (ISSNLinking) **ISSN** Electronic ISSN 1619-7089 PT, PSTYPE Publication type Journal CM Related record Comment In: Eur J Nucl Med Mol Imaging. 2019 Jan; 46(1):8-10. 30310953.; Erratum In: Eur J Nucl Med Mol Imaging. 2019 Jun 26;:. 31240331. JC Journal code 101140988 PBLOC, CP **Publisher location** GERMANY NT Publication model: Notes Print-Electronic; Cited medium: Internet DOI DOI http://dx.doi.org/10.1007/s00259-018-4167-0 PD, YR Publication date Jan 2019 **DCRE** Date created 2018-09-21 **DCOM** Date completed 2019-05-20 **DREV** Date revised 2019-09-03 DSTAT Document status Revised **DSTAT** Medline document status MEDLINE Electronic publication date 2018-09-19 Source attribution Medline, @ Publisher specific AN Accession number 30232539 Document URL http://dialog.proquest.com/professional/docview/2109348521? accountid=174335 FAV First available 2018-09-20 UD Updates 2018-09-20 2018-11-22 2018-11-25 2018-12-20 2018-12-28 2019-03-08 2019-05-21 2019-05-30 2019-06-26 2019-06-27 2019-07-31 2019-08-02 2019-08-07 2019-08-09 2019-09-03 Database MEDLINE® (1946 - current)

# **Search fields**

Field Name	Field Code	Example	Description and Notes
Abstract	АВ	ab(prostate AND treatment)	Use adjacency and/or Boolean operators to narrow or broaden search results.
Abstract present	ABANY	"prostate cancer" AND abany(yes)	Add: AND ABANY(YES) to a query to limit retrieval to records with abstracts. Use double quotes to search a precise phrase.
Accession number	AN	an(30232539)	A unique document identification number assigned by the information provider, NLM.
All fields	ALL	all(("prostate specific membrane antigen" OR PSMA) AND (carcinoma OR cancer))	Searches all fields. Use proximity and/or Boolean operators to narrow or broaden search results.
All fields + text		("prostate specific membrane antigen" OR PSMA) AND (carcinoma OR cancer)	Searches all fields except cited references.
Author <sup>1</sup> Author First Name Author Last Name	AU AUFN AULN	au(sathekge, mike) or au(sathekge, m*) aufn(mike) or aufn(m*) auln(sathekge)	All Authors are included in articles since 2000. Before that date, an abbreviated list may be present.
Author – first author	FAU	fau(mccormack)	The first name listed in Author field. You can look up authors in the author browse list, but you cannot specify it as a first author in the browse list.
Author affiliation	AF	af("steve biko academic hospital") af(virginia) af(germany)	Before 2014, Medline included the affiliation of the first author only. Since 2014 the affiliations of all authors are included when provided by the publisher. Since 2015, multiple affiliations of single authors are included when provided by the publisher.
Author email address	AU	au(up.ac.za)	The author's email address, when available, appears both in the affiliation field and here in its own field

<sup>&</sup>lt;sup>1</sup> A Lookup/Browse feature is available for this field in the Advanced Search dropdown or in Browse fields.

Field Name	Field Code	Example	Description and Notes
CAS® Registry Number <sup>1</sup>	RN	rn(9G34HU7RV0) rn(EC 2.7.10.1) rn(9002-71-5)	Beginning with 2013 MeSH Vocabulary, Registry Number contains Unique Ingredient Identifiers (UNIIs) from the Food and Drug Administration (FDA) Substance Registration System. A zero (0) is a valid value when an actual number cannot be located or is not yet available. Older records may contain the unique 5 to 9 digit number in hyphenated format (Registry Number) assigned by the Chemical Abstracts Service to specific chemical substances. For enzymes, the E.C. number derived from Enzyme Nomenclature appears here. This field is also searchable using the Substance field code (SUBST).
Clinical trial ID	STI	sti(nct02065986) sti("clinicaltrials.gov")	Present in articles about specific clinical trials
Copyright	CY	cy(mccormack)	Not present in all documents
Corporate author	CA	ca("EPE-A study group")	The author of the article when it is an organization or group
Date completed	DCOM	dcom(2019-05-20) dcom(>20190520) dcom(20190101-20190531)	The date on which the NLM completed the record and added MeSH indexing. Date range searching is supported.
Date created	DCRE	dcre(2018-09-21) dcre(>20180630)	The date on which the NLM created the record; it may not have any MeSH indexing at this stage. Date range searching is supported.
Date revised	DREV	drev(2019-09-03) drev(20190903) drev(>20190603)	The date on which the NLM revised the document (it could be years after created/completed dates).  Date range searching is supported

Field Name	Field Code	Example	Description and Notes	
Document status DSTAT		dstat(publisher) dstat("in data review") dstat("in process") dstat.exact(medline) dstat(pubmed-not-medline)	Medline documents have one of the following status types according to its place in the NLM's flow:  Publisher - articles that appear on the web in advance of the journal issue's release (i.e., ahead of print citations)  In data review – first step in the NLM's quality control; records with this value will proceed either to 'In process' or to 'PubMed-not-Medline'  In process – bibliographic data is checked but no MeSH terms are added yet  Medline – complete documents with MeSH indexing and 'Date Completed'; the vast majority of documents in Medline are in this status. Use 'exact' when searching this value to differentiate it from 'pubmed not medline'.  Pubmed-not-Medline – records are not in scope for Medline In addition, you can use dstat to search for revised documents; these are all documents which the NLM has changed for any reason, including when a document is moved from one	
Document title			See Title	
Document type	DTYPE	dtype("clinical trial")	You can select the document type from a list on the Advanced Search page	
DOI	DOI	doi("10.1007/s00259-018-4167-0")	Digital Object Identifier. The portion of the DOI that follows http://dx.doi.org/ is searchable if enclosed in double quotes	
First available	FAV	fav(20180920)	Indicates the first time a document was loaded in Medline on Dialog. It will not change regardless of how many times the record is subsequently reloaded, as long as the accession number stays the same.	

Field Name	Field Code	Example	Description and Notes
From database <sup>2</sup>	FDB	"prostate cancer" AND fdb(medlineprof)  "prostate cancer" AND fdb(10000136)	Useful in multi-file searches to isolate records from a single database. FDB cannot be searched on its own; specify at least one search term then AND it with FDB.
Genetic sequence number	GEN	gen(hm744763)	Molecular sequence data. An article may have a reference to the databank and the accession number assigned to the sequence, and these are included in Medline since 1988. This field is present in less than 1% of Medline documents.
Grant information	GI	gi("medical research council")	If the work described in the article is supported by a grant or sponsorship the name of the fund-giving authority is provided here.
Identifiers (keyword)	IF	if(chemotherapy-naive)	Included in about 10% of Medline documents, identifiers are supplied by partners to the NLM, such as NASA and the Kennedy Institute of Ethics.  Use MeSH for more comprehensive subject searching (see below).
Investigator/ collaborator	IR	ir(weber)	Included in less than 1% of Medline documents, these are the names of individuals who are not authors but are listed in the paper as investigators or collaborators involved in the research
ISSN	ISSN	issn(1619-7070) issn(16197070) issn(1619-7089)	Both the print and the electronic ISSN can be searched with this field code. Also searchable via the Look Up Citation tool.
Issue	ISS	iss(1) iss(supp)	Issue information is also searchable via the Look Up Citation tool.
Journal classification	JCLASS	jclass("abridged index medicus")	The NLM groups journals into very broad subject categories. You can select them from a list on the Advanced Search page. A common one is 'Abridged Index Medicus' which includes Medline's priority journals, i.e. those which are processed before others.

<sup>&</sup>lt;sup>2</sup> Click the "Field codes" hyperlink at the top right of the Advanced Search page. Click "Search syntax and field codes", then click on "FDB command" to get a list of database names and codes that can be searched with FDB.

Field Name	Field Code	Example	Description and Notes
Journal code	JC	jc(101140988)	This is a code assigned to each journal indexed in Medline by the NLM.
Journal title	JN	jn(european journal of nuclear medicine and molecular imaging) jn(nuclear medicine)	A Look up list is available under Publication title. See also Publication title, PUB.
Language	LA	la(english)	The language in which the document was originally published.
Language of abstract	SL	sl(english)	All abstracts in Medline are in English
			Terms from the NLM's Medical Subject Headings vocabulary.
		mesh(heart) mesh.exact(heart) mesh("heart diseases")	mesh(heart) = 'heart' as a single term and as part of a longer phrase (e.g. 'heart diseases') . mesh.exact(heart) = 'heart' as a single
MeSH subject <sup>1</sup>	MESH	mesh.explode("heart diseases")  mesh("heart diseases" su)  mesh("heart diseases" surgery)  mesh.explode("heart diseases" LNK su)	term only.  MeSH terms can be selected from the online thesaurus via the link on the Advanced and Command Line search pages.
		mesh.explode("heart diseases" LNK (su OR dh)) mesh.explode(dipeptides LNK qx)	LNK or is used to combine a main heading with a subheading. Subheadings can be searched as full terms, abbreviations or quick codes (list at end of this ProSheet).
MeSH qualifier	QU	qu(adverse effects) qu(ae)	MeSH subheadings. List available at the end of this ProSheet. QU cannot be used with Major or with quick codes.
Major MeSH subject <sup>1</sup>	MJMESH	mjmesh(actinium – therapeutic use) mjmesh("prostatic neoplasms castration-resistant") mjmesh.explode(dipeptides)	MeSH terms which describe major aspects of the article
Major subject	MJSUB	mjsub(carcinoma)	Alternative to MJMESH for crossfile searching.
MEDLINE document status <sup>1</sup>			See Document status

Field Name	Field Code	Example	Description and Notes
Note	NT	nt(conflict or conflicts) nt(print-electronic) nt(curated)	This includes any conflict of interest statement as well as notes on the publication model and indexing method. The latter may be 'curated' (indexed by a subject matter expert) or 'automated'.
Other ID	RP	RP(KIE G-00059)	"Other ID" is included in documents owned by a collaborating partner of the NLM and contains the organization responsible for the information and a unique number for that document.
Pagination	PG	pg(129-138) pg(377-84)	The start page is searchable on the Look Up Citation page.
Person (as subject)	PER	per(alexander fleming)	A named person who features as a subject of the article. Not the author.
PII	AV	av("S0140-6736(15)00056-2")	The Publisher Item Identifier (PII) is a unique identifier used by scientific journal publishers to identify documents based on an extension of the ISSN. PII is searchable when enclosed in double quotes.
Place of publication	PBLOC	pbloc(germany)	The place of publication of the journal
Publication date	PD	pd(201901) pd(>20181231) pd(20190101 - 20190331) pd(20190102)	Date range searching is supported.
Publication title <sup>1</sup>	PUB	pub(european journal of nuclear medicine and molecular imaging) pub(nuclear) pub("journal of pain research") pub("j pain res")	Journal title. Full title is displayed and searchable; abbreviated form is searchable only. Field code JN also retrieves the journal title, but only in full form, not the abbreviation
Publication type	PSTYPE	pstype(journal)	All records in Medline are from journals.
Publication year	YR	yr(2019) yr(>2018)	
References	RF	rf("lancet oncol" lnk 2018)	References to other Medline articles are present in about 9% of documents. Journal name, year, volume, issue and pages are given, as well as the accession number of the referenced article.
Related record	СМ	cm("eur j nucl med mol imaging. 2019 Jan;46(1)")	Comments, errata and notes on other articles are present in about 2% of documents

Field Name	Field Code	Example	Description and Notes
Subject	SU	su(prostate)	Use SU to search both MeSH terms (MESH) and Identifiers (IF).
Subject	SUB		Same as SU
Substance	SUBST	subst("actinium-225") subst(NIK1K0956U)	The number (but not the substance name) is also searchable using search field (RN) – see notes above on CAS Registry Number.
Title	TI	ti(advanced prostate cancer pilot)	Includes the Title, Foreign Language Title, Alternate Title and Subtitle, when available.
Title only	TIO	tio("pilot study")	Searches only the Title, not Subtitle or Alternate Title.
Original title	ОТІ	oti(zellzykluskontrolle und krebs)	Original-language document title.
Updates	UD	ud(20190903)	The date(s) the record was loaded as a result of an update provided by the supplier. If there is more than one, only the latest is searchable.
Volume	VO	vo(46)	Volume is also searchable via the Look Up Citation tool.

### **Search tools**

Field codes are used to search document fields, as shown in the sample document. Field codes may be used in searches entered on the **Basic Search**, **Advanced Search**, and **Command Line** search pages. **Limit options**, **Look up lists**, and **"Narrow results by" filters** tools are available for searching. Some data can be searched using more than one tool.

# **Limit options**

Limit options are quick and easy ways of searching certain common concepts. On the Advanced search page check boxes are available for:

Humans, Animals, Males, Females, Reviews, Clinical Trials, Abstract included

Short lists of choices are available for:

Document type, Language, Age group, Document status, Journal classification

**Date limiters** are available in which you can select single dates or ranges for dates **published**, **updated** and **created** (by the NLM).

## **Command line common concepts**

Search common concepts as follows:

ABANY(YES), HUMAN(YES), ANIMAL(YES), FEMALE(YES), MALE(YES)

Find review articles with the strategy:

DTYPE(REVIEW OR "META ANALYSIS" OR "CONSENSUS DEVELOPMENT CONFERENCE" OR GUIDELINE)

Find clinical trials with the strategy:

DTYPE("CLINICAL TRIAL\*" OR "CONTROLLED CLINICAL TRIAL" OR "MULTICENTER STUDY" OR "RANDOMIZED CONTROLLED TRIAL" OR "EQUIVALENCE TRIAL") OR MESH.EXACT.EXPLODE("CLINICAL TRIALS AS TOPIC")

Find priority journals with the strategy: JCLASS("ABRIDGED INDEX MEDICUS")

### **Browse fields**

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced search form. Look Up lists are available on the Advanced search page in the fields drop-down and in the search options for:

Author, CAS® Registry Number, Major MeSH, MeSH, Publication title

### **Thesaurus**

The MeSH vocabulary is available by clicking on the "Thesaurus" hyperlink on the right side of the Advanced Search and the Command Line Search pages. Terms may be searched within the thesaurus, then selected to be added automatically to the search form.

# "Narrow results By" filters

When results of a search are presented, the results display is accompanied by a list of "Narrow results by" options shown on the right-hand panel. Click on any of these options and you will see a ranked list showing the most frequently occurring terms in your results. Click on term(s) you wish to include or exclude and apply them to ("narrow") your search results. "Narrow results by" filters in MEDLINE include

Document type, Author, CAS® Registry number, Language, MeSH, Major MeSH, Publication title, Journal classification, Publication date

### Look up citation

If you need to trace a particular bibliographic reference, use the Look Up Citation feature. Find a link to this toward the top left-hand corner of the Advanced Search page, or in the drop list under Advanced on any search form; click this and you will go to a page where you can enter any known details of the citation, including document title, author, journal name, volume, issue, page, publication date, ISSN.

### **Notes**

#### Document Status

The status of the MEDLINE document is indicated by one of five phrases:

PUBLISHER, IN-DATA-REVIEW, IN-PROCESS, MEDLINE and PUBMED-NOT-MEDLINE.

A document can be in any one of these stages, but the vast majority of them are 'MEDLINE', i.e., reviewed, verified and fully indexed with MeSH headings. 'Publisher', 'In-Data-Review' and 'In-Process' documents are put into MEDLINE quickly to ensure currency of the information; they have no MeSH headings and may not be fully verified.

'Publisher' articles are those appearing on the Web before they have been assigned to a specific journal issue so they may not yet have full bibliographic details. 'In-Data-Review' documents are at the first stage of review and verification, and 'In-Process' are at the second – author names, article titles and pagination are checked.

All of these 'in-processing' types subsequently undergo complete quality review by the NLM, and most are indexed and moved into complete MEDLINE status. At this point they are sent to Dialog's MEDLINE again when they overwrite the earlier in-process records.

A few documents remain out of MEDLINE's usual scope and are not indexed with MeSH, though they stay in the database and have full bibliographic information; these are the 'PubMed-not-MEDLINE' records.

You can see these status indicators in the 'MEDLINE document status' field, and search them using the field code DSTAT or choose an option from the short 'Document status' check-box list.

Search as:

#### dstat(in-process OR in-data-review)

dstat.exact(medline) - it is important to use 'exact' here, to differentiate 'MEDLINE' from 'Pubmed-not-MEDLINE'.

Publisher, In-Process and In-Data-Review records are added daily to MEDLINE.

#### Annual Reload

The NLM makes changes every year to the MeSH thesaurus to reflect changing medical terminology. New terms are added, some are changed and old terms are deleted. Every December the NLM provides a complete reload of MEDLINE to incorporate these MeSH changes.

#### Revised Documents

The NLM carries out a continuous program of editing and revising documents as new information about older records becomes available. Three fields towards the end of the document display the dates on which the record was created, completed and revised.

Editorial revisions might consist of changes to journal names, abbreviations or ISSNs, or the addition of Registry numbers or internal NLM fields. The NLM does not indicate the nature of the revision when they supply these documents.

In addition, every document is flagged as revised when it moves from one status to another, such as from 'In-Process' to 'MEDLINE'. This application of 'revised' to changes in document status was introduced in October 2016.

Occasionally the period between the date on which the record was created and the date on which it was revised or completed is long – sometimes many years. It can therefore happen that a document created in 1975 was revised or completed in 2019. When revised or completed, the document enters the database again (as described above, as part of the review/completion process). Such documents will appear in the results of your searches and sometimes the NLM supplies large batches of them; if you wish to minimize the number of older records with editorial changes in your results, add a recent publication year range to your strategy, e.g. **AND py(>2017)**, or a "date created" or "first available" limiter, e.g. **AND dcre, fav(>20170101)** 

### **Document formats**

Document Format	Fields	Online	Export/ Download
Brief view	Title and Publication date	✓	
Detailed view	Same as Brief view plus a 3-line KWIC window	✓	
KWIC (Keyword in context)	Detailed view plus all occurrences of your search terms, highlighted within the fields where the terms occur	✓	✓
Preview (subscribers only)	Title, Author, Publication title, Volume, Issue, Pagination, Publication date, Abstract, Subject	✓	
Preview (transactional)	Title, Publication date, abbreviated Abstract	✓	
Brief citation	Bibliographic record minus Abstract, Indexing and References	✓	✓
Citation / Abstract	Complete record	√3	<b>√</b>
Custom	Choose the fields you want	✓	<b>√</b> 4

<sup>&</sup>lt;sup>3</sup> In Online-view mode, Dialog gives access to two document formats only: Brief citation, and the 'most complete' format available. Depending on the database, or the amount of data available for a record, the most complete format may be any one of Citation, Citation/Abstract, Full text, or Full text – PDF.

<sup>&</sup>lt;sup>4</sup> Custom export/download format is available in the following mediums only: HTML, PDF, RefWorks, RTF, Text only, XLS.

# MeSH subheadings

MeSH subheadings (or qualifiers) are used to define the context of a main MeSH heading. An article indexed with "aripiprazole – adverse effects" informs the reader that the article is about the drug aripiprazole and specifically about the adverse effects of it. MeSH terms and subheadings can be selected from the online thesaurus via the link on the Advanced and Command Line search pages. For ease of reference the subheadings are also reproduced below. Subheadings can be searched as full terms, abbreviations or as a quick code for a group of subheadings (list of MeSH subheading quick codes follows the full list below). Not all subheadings can be combined with every main MeSH heading; a MeSH heading's allowable subheadings are indicated in the online thesaurus.

Use LNK or -- to combine a main heading with a subheading, e.g.:

mesh(aripiprazole – ae) mesh.explode("antipsychotic agents" LNK qx)

MeSH subheading	Abbreviation	Isolation and purification	ΙP
Abnormalities	AB	Legislation and jurisprudence	 LJ
Administration and dosage	AD	Manpower	MA
Adverse effects	AE	Metabolism	ME
Agonists	AG	Methods	MT
Analogs and derivatives	AA	Microbiology	MI
Analysis	AN	Mortality	MO
Anatomy and histology	AH	Nursing	NU
Antagonists and inhibitors	Al	Organization and administration	OG
Biosynthesis	BI	Parasitology	PS
Blood	BL	Pathogenicity	PY
Blood supply	BS	Pathology	PA
Cerebrospinal fluid	CF	Pharmacokinetics	PK
Chemical synthesis	CS	Pharmacology	PD
Chemically induced	CI	Physiology	PH
Chemistry	CH	Physiopathology	PP
Classification	CL	Poisoning	PO
Complications	CO	Prevention and control	PC
Congenital	CN	Psychology	PX
Cytology	CY	Radiation effects	RE
Deficiency	DF	Radiotherapy	RA
Diagnosis	DI	Rehabilitation	RH
Diagnostic imaging	DG	Secondary	SC
Diet therapy	DH	Secretion	SE
Drug effects	DE	Standards	ST
Drug therapy	DT	Statistics and numerical data	SN
Economics	EC	Supply and distribution	SD
Education	ED	Surgery	SU
Embryology	EM	Therapeutic use	TU
Enzymology	EN	Therapy	TH
Epidemiology	EP	Toxicity	TO
Ethics	ES ES	Transmission	TM
Ethnology	EH	Transplantation	TR
Etiology	ET	Trends	TD
Genetics	GE	Ultrastructure	UL
Growth and development	GD	Urine	UR
History	HI	Utilization	UT
Immunology	IM	Veterinary	VE
Injuries	IN	Virology	VI
Innervation	IR	<del></del>	
Instrumentation	IS		

## MeSH subheading quick codes

MeSH quick subheading group Quick anatomy (AH BS CY PA UL EM AB IR) Quick embryology (EM AB) Quick chemistry (CH AG AA AI CS) Quick diagnosis (DI PA) Quick etiology (ET CI CO SC CN EM GE IM MI VI PS TM) Quick surgery (SU TR) Quick microbiology (MI VI) Quick complications (CO SC) Quick metabolism (ME BI BL CF DF EN PK UR) Quick analysis (AN BL CF IP UR) Quick organization (OG EC LJ MA ST SD TD UT) Quick pharmacology (PD AD AE PO TO AG AI DU PK) Quick statistics (SN EP EH MO SD UT) Quick therapy (TH DH DT NU PC RT RH SU TR) Quick epidemiology (EP EH MO) Quick epidemiology (EP EH MO)	Abbreviation QA QB QC QD QE QG QK QL QM QN QO QP QS QT QU QW QY
,	

#### **Terms & Conditions**

### **MEDLINE/PUBMED SPECIFIC TERMS**

NLM freely provides PubMed/MEDLINE data. Please note some PubMed/MEDLINE abstracts may be protected by copyright.

### **GENERAL TERMS AND CONDITIONS**

Users of the data agree to:

- acknowledge NLM as the source of the data in a clear and conspicuous manner.
- o properly use registration and/or trademark symbols\_when referring to NLM products, and
- o not indicate or imply that NLM has endorsed its products/services/applications.

Users who republish or redistribute the data (services, products or raw data) agree to:

- o maintain the most current version of all distributed data, or
- o make known in a clear and conspicuous manner that the products/services/applications do not reflect the most current/accurate data available from NLM.

These data are produced with a reasonable standard of care, but NLM makes no warranties express or implied, including no warranty of merchantability or fitness for particular purpose, regarding the accuracy or completeness of the data. Users agree to hold NLM and the U.S. Government harmless from any liability resulting from errors in the data. NLM disclaims any liability for any consequences due to use, misuse, or interpretation of information contained or not contained in the data.

NLM does not provide legal advice regarding copyright, fair use, or other aspects of intellectual property rights. See the NLM Copyright page.

NLM reserves the right to change the type and format of its machine-readable data. NLM will take reasonable steps to inform users of any changes to the format of the data before the data are distributed via the announcement section or subscription to email and RSS updates.

### **Dialog Standard Terms & Conditions** apply.

Contact: **Dialog Global Customer Support** Email: Customer@dialog.com

Within North America 1 800 334 2564 Outside North America 00 800 33 34 2564